Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danduqing Granules is a Traditional Chinese Medicine (TCM) candidate developed by the Qingdao Haichuan Innovative Natural Medicine Research Center for the treatment of erysipelas, specifically targeting the damp-heat and toxin syndrome. Erysipelas is an acute bacterial infection of the dermis and superficial lymphatics, typically caused by *Streptococcus pyogenes*, which presents as well-demarcated, erythematous, and edematous skin lesions. The formulation is designed to clear heat, resolve toxins, and cool the blood, addressing the underlying TCM etiology of fire-toxin accumulation. Clinical development in China has evaluated the efficacy of Danduqing Granules in reducing both local symptoms, such as skin redness and pain, and systemic symptoms like fever, potentially serving as an alternative or adjunct to conventional antibiotic therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Danduqing Granules.